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Data also indicates that COPD is
three times more common than
previously estimated. COPD therefore
poses a significant public health
problem. While other chronic diseases,
such as cardiovascular disease, are on
the decrease, COPD is on the increase.
The Global Initiative for Chronic
Obstructive Lung Disease, GOLD, of
which Malta forms a part, is conducted
in collaboration with the US National
Heart, Lung, and Blood Institute
(NHLBI) and the World Health
Organisation (WHO). The overall aim of
GOLD is to increase awareness of COPD
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Chronic obstructive pulmonary disease (COPD) is currently a
major cause of morbidity and mortality throughout the world.
The disease responsible for an estimated 2.75 million deaths
each year, ranking it as the fourth leading cause of death.
Recent data published from the Burden of Obstructive Lung
Disease Study estimates that at least 10% of the world’s
population over 40 years of age may be suffering from COPD.
Diagnosing COPD
Chronic obstructive pulmonary
disease is characterised by airflow
limitation that is not completely
reversible. This airflow obstruction is
progressive and is associated with an
abnormal inflammatory response of the
lungs to noxious particles or gases such
as cigarette smoke, occupational dusts
and chemicals, environmental tobacco
smoke and indoor/outdoor air
pollution. Most patients present with
cough, which either precedes the onset
of breathlessness or appears
concurrently with it. Chronic cough and
sputum production can precede
development of airflow limitation by
many years, although not all individuals
with cough and sputum production go
on to develop COPD. Other symptoms
may include wheezing, chest tightness,
haemoptysis and, at an advanced stage,
anorexia and weight loss.
Spirometry is necessary for
definitive and accurate diagnosis of
COPD. Spirometry is the gold standard
as it is the most reproducible,
standardised and objective way of
measuring airflow limitation. A finding
of FEV1 of less than 80% of the
predicted value after bronchodilation
and a FEV1/FVC ratio below 70%
predicted confirms the presence of
airflow limitation that is not fully
reversible. Serial measurements of FEV1
are essential to monitor disease
progression, and a fall of more than
50ml/l per year implies accelerated
decline. GOLD recommends that health
care professionals involved in the
diagnosis and management of COPD
patients should have access to
spirometry.
Targeting COPD in primary
health care
Due to low symptom awareness,
COPD is not usually diagnosed before it
is at a moderately advanced stage and
significantly affecting a person’s quality
of life. Early diagnosis enables
initiation of appropriate prevention and
treatment strategies. Diagnosing COPD
in primary health care is an effective
means of helping people at an early
stage. For this reason GOLD has
developed the ‘Could it be COPD?’
questionnaire (Table 1). This
questionnaire consists of 5 simple
questions about COPD symptoms. It is
mainly a self-assessment questionnaire
which can be conducted by the
individual in just over 30 seconds.  If
the person has answered yes to 3 or
more questions he/she is encouraged to
1. Do you cough several times most days? Yes No
2. Do you bring up phlegm or mucus most days? Yes No
3. Do you get out of breath more easily than others your age? Yes No
4. Are you older than 40 years? Yes No
5. Are you are current or an ex-smoker? Yes No
If you have answered yes to three or more questions, ask your doctor if you might have COPD
and should have a simple breathing test.
Table 1: Could it be COPD?
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ask the doctor to investigate the
possibility of COPD by having a simple
breathing test done. The questionnaire
in Table 1 can be very easily reproduced
by health care professionals. It can be
made available at the waiting area of a
doctor’s clinic. It can also be made
available through community
pharmacies. Pharmacists can identify at
risk patient as those who regularly ask
for cough preparations, or whom they
know to be smokers/ex-smokers or who
complain of being short of breath.
These could be encouraged to take the
questionnaire and if appropriate
referred to a doctor for further
investigation. The questionnaire may
also have a poster format which may be
placed in a doctor’s clinic or a
pharmacy. This is an effective means of
increasing awareness among health care
professionals and the general public.
Prevention and treatment
of COPD
Since cigarette smoking is the major
cause of development of COPD, smoking
cessation is the single most effective
way to arrest its progression. Every
contact between health care
professionals and smokers should be
used to reinforce advice about smoking
cessation. This message is strengthened
by linking smoking to signs and
symptoms of the disease.
Pharmacotherapy, such as nicotine
replacement and bupropion, should be
appropriately prescribed in the absence
of any other contraindications.
Healthcare professionals should
maintain contact with persons
attempting smoking cessation and offer
ongoing support. Follow up of these
persons on a regular basis enhances the
chance of a sustained successful
outcome.
Therapeutic management of COPD
should be characterised by a stepwise
increase in the treatment depending on
severity of the disease. Table 2 provides
an overview of the therapy at each
stage of COPD.
Bronchodilators are central to the
symptomatic treatment of COPD.
Depending on the severity, inhaled
bronchodilators may be given on a
regular basis to prevent and control
symptoms or on a prn basis for relief.
Inhaled bronchodilators used in COPD
are ß2 agonists, which may be short
acting (eg salbutamol, terbutaline) or
long acting (salmeterol, formoterol)
and anticholinergics which may also be
short-acting (ipratropium) or long
acting (tiotropium). The use of
methylxanthines are restricted due to
side effects and narrow therapeutic
window.
Inhaled glucocorticoids are of
limited use among patients with COPD,
except in those presenting with
repeated exacerbations.  In such cases
inhaled glucocorticoids have been
shown to reduce the frequency of
exacerbations and improve quality of
life.  Recent evidence has shown that
inhaled glucocortcoids combined with
long acting ß
2
 agonists are more
effective than the individual
components.
Oxygen therapy is the principal
component of treatment for patients
with very severe COPD. Long term
oxygen given at this stage has been
shown to increase life expectancy.
Conclusion
In 2002, under the auspices of GOLD
and the academic sponsorship of the
University of Malta, the Department of
Health, the Malta College of Pharmacy
Practice and the Malta College of Family
Doctors, The Malta Guidelines for the
Management of Chronic Obstructive
Pulmonary Disease were published and
distributed to health care professionals.
This was a first step towards sensitising
health care professionals to the
problem of COPD. The fight against
COPD, however, needs a continuous
concerted effort by health care
professionals, policy makers and public
health officials. It is also necessary to
increase awareness among the general
public.
Mild Short-acting bronchodilator prn
Moderate Short-acting bronchodilator prn,
Regular treatment with one or more long-acting bronchodilators
Rehabilitation
Severe Short-acting bronchodilator prn,
Regular treatment with one or more long-acting bronchodilators
Inhaled glucocorticoids if there is significant symptomatic and lung
  function response or repeated exacerbations
Rehabilitation
Very Severe Short-acting bronchodilator prn,
Regular treatment with one or more long-acting bronchodilators
Inhaled glucocorticoids if there is significant symptomatic and lung
  function response or repeated exacerbations
Treatment of complications
Rehabilitation
Long term oxygen therapy if there is chronic respiratory failure.
Table 2: Therapy at each stage of COPD
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